Pancreatic cancer is one of the deadliest forms of cancer—because it’s often diagnosed too late. But with new technologies in genomics, imaging, and liquid biopsy, we are beginning to change that story.
At Human Longevity, Inc., we believe in early, personalized prevention. And when it comes to pancreatic cancer, the question we need to ask is: Who should be screened more proactively?
Here are the groups who should take pancreatic cancer screening seriously:
- Individuals with family history of pancreatic, breast, ovarian, or melanoma cancers
- People with genetic mutations like BRCA2, PALB2, or CDKN2A
- Adults over 50 with new-onset diabetes
- Anyone with pancreatic cysts or chronic inflammation
- Executives and health-conscious individuals who want to detect silent disease before symptoms
At HLI, we use a multi-modal strategy:
- Whole genome sequencing to understand inherited risk
- Whole-body MRI (including pancreatic imaging) to detect hidden tumors with no radiation
- Longitudinal biomarker tracking (e.g., CA19-9, thrombospondin-2)
- And now, we’ve added the Avantect® Pancreatic Cancer Test, a cutting-edge liquid biopsy that can detect early-stage pancreatic cancer through a simple blood draw—before it’s visible on imaging.
We’ve seen firsthand how combining data—genetic, molecular, and anatomical—can save lives by identifying cancer early, when it’s still curable.
Pancreatic cancer doesn’t have to be a death sentence. With the right tools and the right timing, we can shift from late-stage treatment to early-stage prevention.
If you’re in one of these higher-risk groups, or building a strategy for executive health, now is the time to act.
Let’s not wait for symptoms.